key: cord-0950912-i3sidkq4
authors: Schrörs, Barbara; Gudimella, Ranganath; Bukur, Thomas; Rösler, Thomas; Löwer, Martin; Sahin, Ugur
title: Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates
date: 2021-03-15
journal: bioRxiv
DOI: 10.1101/2021.02.04.429765
sha: ca40175b2b4375ea6e0e8b94ef589a23963b1519
doc_id: 950912
cord_uid: i3sidkq4

Due to the widespread of the COVID-19 pandemic, the SARS-CoV-2 genome is evolving in diverse human populations. Several studies already reported different strains and an increase in the mutation rate. Particularly, mutations in SARS-CoV-2 spike-glycoprotein are of great interest as it mediates infection in human and recently approved mRNA vaccines are designed to induce immune responses against it. We analyzed 146,917 SARS-CoV-2 genome assemblies and 2,393 NGS datasets from GISAID, NCBI Virus and NCBI SRA archives focusing on non-synonymous mutations in the spike protein. Only around 13.8% of the samples contained the wild-type spike protein with no variation from the reference. Among the spike protein mutants, we confirmed a low mutation rate exhibiting less than 10 non-synonymous mutations in 99.98% of the analyzed sequences, but the mean and median number of spike protein mutations per sample increased over time. 2,592 distinct variants were found in total. The majority of the observed variants were recurrent, but only nine and 23 recurrent variants were found in at least 0.5% of the mutant genome assemblies and NGS samples, respectively. Further, we found high-confidence subclonal variants in about 15.1% of the NGS data sets with mutant spike protein, which might indicate co-infection with various SARS-CoV-2 strains and/or intra-host evolution. Lastly, some variants might have an effect on antibody binding or T-cell recognition. These findings demonstrate the increasing importance of monitoring SARS-CoV-2 sequences for an early detection of variants that require adaptations in preventive and therapeutic strategies.

Since the first report of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak 37

(1, 2), it has transformed into a global pandemic infecting and threatening death for millions of people 38 all over the globe. By January 20, 2021, the World Health Organization (WHO) reported 94,124,612 39 confirmed cases and 2,034,527 deaths caused by the SARS-CoV-2 outbreak (3). On verge of the 40 approval of SARS-CoV-2 vaccines which are designed to invoke immune responses against the spike-41 glycoprotein (spike protein), it becomes necessary to track the mutations in spike protein and study their 42 relevance for current and upcoming vaccines. Also the recently approved neutralizing antibody 43 bamlanivimab targets the spike protein of SARS-CoV-2 (4). 44

Subunits of the spike protein are valuable targets for vaccine design as the protein is responsible for 45 viral binding and entry to host cells (5, 6). The spike protein consists of the N-terminal S1 and the C-46 terminal S2 subunits; the receptor-binding domain (RBD) in the S1 subunit binds to a receptor on the 47 host cell surface and the S2 subunit fuses viral and host membranes (7). The receptor binding domain 48 (RBD) of the SARS-CoV-2 spike protein recognizes human angiotensin-converting enzyme 2 (ACE2) 49 as its entry receptor, similar to SARS-CoV (8). Interacting residues of the SARS-CoV-2 RBD with 50 human ACE2 are highly conserved or share similar side chain properties with the SARS-CoV RBD (9). 51

In addition, the SARS-CoV-2 RBD shows significantly higher binding affinity to ACE2 receptor 52 compared to the SARS-CoV RBD. In order to repress the infection, blocking the RBD binding was 53 effective in ACE2-expressing cells (5). Among the interacting sites in the SARS-CoV-2 RBD, 54 particularly the amino acid residues L455, F486, Q493, S494, N501, and Y505 provide critical 55 interactions with human ACE2 (10). These interacting residues vary due to natural selection in SARS-56

CoV-2 and other related coronaviruses (11). Similarly, worldwide SARS-CoV-2 genomic data shows 57 ten RBD mutations which were caused due to natural selection by circulating among the human 58 population (12) . RBD mutations particularly at N501 may enhance the binding affinity between SARS-59

CoV-2 and human ACE2 significantly, improving viral infectivity and pathogenicity (10). 60

It is reported that continuous evolution of SARS-CoV-2 among the global population results into six 61 major subtypes which involve the recurrent D614G mutation of the spike protein (13). Further, spread 62 of such recurrent mutations within sub-populations might affect the severity of disease emergence and 63 change the trajectory of the pandemic. Studies also report high intra-host diversity caused by low 64 frequency subclonal mutations within a specific cohort (14). It is evident that changes in the SARS-65

CoV-2 genome over time might show new mutations which might influence the development efforts of 66 of interventional strategies. The variability of epitopes of the RBD might hamper the development and 67 use of neutralizing antibodies for cross-protective activities against mutant strains (15). Mutational 68 variants of the spike protein might as well lead to escape variants with respect to pre-existing cross-69 reactive CD4+ T cell responses (16) or long-term protection from re-infection through T cell memory. 70

Hence, there is a necessity of constant monitoring of the rapidly changing mutation rates in the spike 71 protein in SARS-CoV-2, which could have significant impact on virus infection, transmissibility and 72 pathogenicity in the current pandemic. 73

In this study, we gathered 147,413 genomic assemblies and 2,393 NGS sequencing datasets to detect 74 non-synonymous spike protein mutations and infer their frequency within a given sample and the effect 75 on potential antibody binding sites and known T cell epitopes. For three sequences obtained from NCBI Virus (accession IDs: QOE35701, QIQ50182, and QIQ50192), 89 corresponding NGS data was available at the NCBI Sequence Read Archive (SRA, see section "NGS 90 data processing"). Variant calling in the spike protein was in concordance between the assembly and the 91 NGS data. Therefore, only the NGS data was used for further analysis. 92 NGS data processing 93 All available NGS data for SARS-CoV-2 was downloaded on October 14 th , 2020 from the NCBI SRA 94 (20,246 samples) contained the WT spike protein (Fig 1A) . Samples of mutant viruses exhibited only 126 few mutations in the spike protein with less than ten mutations for all but 35 sequences. However, the 127 mean and median number of mutations increased over time from December 2019 (mean: 0.14, median: 128 0) to September 2020 (mean: 2, median: 2; Fig 1B) . Overall, we detected 2,592 distinct non-synonymous 129 mutations in the spike protein (Supplementary Table S1 ). 

Most of the observed variants in the assembly and NGS data sets were recurrent (Fig 2A) and only 33.2% of the variants were singular events in the combined assembly and the NGS data. The recurrent variants were distributed throughout the whole spike protein (Fig 2B, C) . Among the recurrent variants, nine and 23 mutations were found in at least 0.5% of the mutant assembly and NGS samples, respectively (labeled variants in Fig 2 B , C). The most common mutation was D614G in both the genome assemblies (124,178 samples) and the NGS data (1,792 samples) located outside the RBD (positions 319-529), followed by the RBD variants S477N in the assemblies (11,483 samples) and N440K in the NGS data (75 samples). In total, 339 distinct mutations (227 recurrent) were detected in the RBD in the assemblies out of which only two were common to more than 0.5% of the mutated assembly sequences (Fig 2A) . For the NGS samples, 61 mutations in total (24 recurrent) were found in the RBD (Fig 2B) and again only two were detected in at least 0.5% of the mutant NGS samples. Overall, 246 mutations were commonly found in the assembly and NGS data (Fig 2C) .

Furthermore, 72 (2.8%) of the detected variants co-occurred frequently in at least 100 of the mutated spike protein sequences when we combined assembly and NGS data (Fig 2D) . Most prominent here, was the variant D614G which was found in combination with 1,385 other variants. The combination S477N/D614G was detected in 11,470 samples. These represented the above mentioned two most frequent variants in the assembly data. The most frequent co-occurring mutations not involving D614G were L18F/A222V (1025 samples). with mutant spike protein) that could be classified as high-confident subclonal (Fig 3B) . Most of these 150 subclonal events were recurrent variants (Fig 3C) . Especially in the earlier samples, but also in some 151 later cases, the fractions of supporting reads within the same sample differed notably. Next, we investigated whether the observed spike protein variants were relevant in the context of 164 antibody binding or T cell recognition. In order to be visible for antibodies, a mutation has to hit a 165 residue on the surface of the trimeric spike protein complex. 432 (16.7%) of 2,592 unique variants 166 affected surface residues. For the 20 most frequent among these occurring in at least 50 samples, the 167 change in SASA from wild type to mutation at the mutated residue position was investigated (Fig 4A) . 168

The SASA changed for all but one (H245Y) of the variants which might influence the accessibility of 169 neutralizing antibodies. Furthermore, 2,544 (98.1%) of the 2,592 distinct variants hit at least one CD8+ 170 or CD4+ T-cell epitope (Fig 4B) The RBD of the spike protein is a potential target for neutralizing antibodies and the variants in these 206 regions might influence the infectivity and pathogenicity. We have identified high frequency variants in 207 the RBD region from the assembly data, i.e. S477N, N439K, N440K and G413V (Fig 2B, C) . S477N 208 occurs frequently almost similar to the D614G variant and studies show that S477N has potential to 209 affect the RBD stability and strengthen the binding with the human ACE2 protein (37, 38). In our study, 210 S477N was most frequently co-occurring with D614G ( Fig 2D) . This combination was estimated to 211 spread more rapidly than the D614G mutant alone (39). Other RBD variants such as N439K and N440K 212 also show enhanced binding affinity to the human ACE2 receptor and result in immune escape from a 213 panel of neutralizing monoclonal antibodies (40-42). Antibody-resistant RBD variants might affect the 214 therapeutic potential of neutralizing monoclonal antibodies by escaping through disruption of epitopes. 215

However, a significant portion of the detected variants represent individual events based on what could 216 be deduced from the available data. This indicates the necessity to further collect SARS-CoV-2 isolates 217 and monitor newly occurring variants. Here, the combination of assembly data (which appeared to be 218 available in a timelier manner) and NGS samples (which also contain information on the clonality of 219 the observed variants but which might be deposited with some delay) provide a valuable resource. 220 The analyzed data sets also showed that a notable portion of the individual and recurrent mutations in 231 the spike protein (98.1%) overlap with at least one known T-cell epitope. They also may change the 232 solvent-accessible area and thus antibody binding when they involve surface residues of the trimeric 233 spike protein complex as shown for the 20 most frequent solvent-accessible mutations. While we had 234 no information on the HLA-restriction of the published T-cell epitopes, the influence on CD8+ T cell 235 epitope generation by different HLA alleles was investigated for the three common mutations L5F, 236 D614G and G1124V (44) . These mutations were predicted to result in epitope gains, losses or higher or 237 lower HLA binding affinities. Greaney et al. (45) presented a system to map mutations in the SARS-238

CoV-2 RBD that escape antibody binding. However, there is no overlap with our exemplary analysis on 239 SASA changes. In agreement with the increase of the SASA of the mutation N440K, the binding affinity 240 of this mutant to antibody REGN10933_REGN10987 is strengthened (46). All these findings 241 demonstrate that SARS-CoV-2 mutants need to be set in the context of immune recognition to evaluate 242 their implications for the global spreading of the pandemic and future preventive or therapeutic 243 approaches in a timely manner. 244

Human infections with SARS-CoV-2 are spreading globally since the beginning of 2020, necessitating 246 preventive or therapeutic strategies and first steps towards an end to this pandemic were done with the 247 approval of the first mRNA vaccines against SARS-CoV-2. Here, we show different types of variants 248 (recurrent vs. individual, clonal vs. subclonal, hitting T-cell or antibody target sites vs. not-hitting) that 249 can be incorporated in global efforts to sustainably prevent or treat infections. The underlying 250 computational strategy might serve as a template for a platform to constantly analyze globally available 251 sequencing data. In combination with a web-based platform to administer the results, this could help 252 guiding global vaccine design efforts to overcome the threats of this pandemic. 253

The importance of our approach is underlined by the recently emerging UK lineage B.1.1.7 of SARS-254

CoV-2 (47), which is characterized by the accumulation of 17 variants; eight of those are located in the 255 S protein. This lineage has a higher transmissibility compared to other lineages (48). The occurrence of 256 this lineage questioned the efficacy of current vaccines, but first results showed that it at least unlikely 257 will escape BNT162b-induced protection (49). Interestingly, the individual variants can be traced back 258 to samples from March (P681H, T716I) and April (Y144del, N501Y, A570D) of 2020. It needs to be 259 mentioned that the available data, although representing a large cohort, might not reflect the real 260 distribution of the circulating variants as mostly samples of specific interest will be sequenced. 261

International sequencing efforts, combined data analysis and prediction of variant impact will be 262 important tools for the future in order to ensure an early detection of such genomic variants of concern. 263

A Novel Coronavirus from Patients with 278 Pneumonia in China

A new coronavirus associated with 280 human respiratory disease in China

WHO Coronavirus Disease (COVID-19) Dashboard: Data last updated: 282 2021/1/19, 6:44pm CET; 2021

Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted 284 patients

Characterization of the receptor-binding 286 domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral 287 attachment inhibitor and vaccine

The outbreak of SARS-CoV-2 pneumonia calls for viral 289 vaccines

Structure, Function, and Evolution of Coronavirus Spike Proteins

A pneumonia outbreak associated 293 with a new coronavirus of probable bat origin

Structure of the SARS-CoV-2 spike receptor-295 binding domain bound to the ACE2 receptor

Receptor Recognition by the Novel Coronavirus from 297 Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

On the origin and continuing evolution of 300 SARS-CoV-2

RBD mutations from circulating SARS-CoV-2 302 strains enhance the structural stability and human ACE2 affinity of the spike protein

The global population of 304 SARS-CoV-2 is composed of six major subtypes

Within-patient 306 genetic diversity of SARS-CoV-2

SARS-CoV-2 and SARS-CoV spike-RBD 308 structure and receptor binding comparison and potential implications on neutralizing antibody and 309 vaccine development

Presence of SARS-CoV-2 311 reactive T cells in COVID-19 patients and healthy donors

Resource -improved response to emergent viral outbreaks

disease and diplomacy: GISAID's innovative contribution to 316 global health

The sequence read archive

NCBI viral genomes resource

Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM

The Sequence Alignment/Map 324 format and SAMtools

A program for annotating 326 and predicting the effects of single nucleotide polymorphisms

Drosophila melanogaster strain w1118; iso-2; iso-3

Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for 331 comparative protein modeling

Magnitude and 333 Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

Discovery of 336 an RNA virus 3'-5' exoribonuclease that is critically involved in coronavirus RNA synthesis

We shouldn't worry when a virus mutates during disease 339 outbreaks

Coronavirus SARS-CoV-2: Filtering fact from fiction in the infodemic: Q&A with 341 virologist Professor Urs Greber

Tracking Changes in 343 SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Emergence of genomic 345 diversity and recurrent mutations in SARS-CoV-2

No evidence for increased 347 transmissibility from recurrent mutations in SARS-CoV-2

The D614G mutation of SARS-CoV-2 349 spike protein enhances viral infectivity

Spike mutation D614G alters 352 SARS-CoV-2 fitness

SARS-CoV-2 D614G spike mutation 354 increases entry efficiency with enhanced ACE2-binding affinity

Making Sense of Mutation: What D614G Means for 356 the COVID-19 Pandemic Remains Unclear

Deep Mutational 358 Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 359 Binding

Serine 477 plays a crucial role in the 361 interaction of the SARS-CoV-2 spike protein with the human receptor ACE2

Statistical challenges in the analysis of sequence and structure data for the 363 COVID-19 spike protein

N439K variant in spike protein may alter 365 the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation: 366 bioRxiv

The 368 circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated 369 immunity: bioRxiv

Escape from neutralizing 371 antibodies by SARS-CoV-2 spike protein variants

SARS-CoV-2 genome evolution exposes early human 373 adaptations

CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike 375 protein in genetically diverse human population: Implications for disease control and prevention

Complete Mapping of 378 Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Prediction and mitigation of mutation threats to COVID-19 381 vaccines and antibody therapies

Preliminary genomic 383 characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike 384 mutations: COVID-19 Genomics Consortium UK (CoG-UK)

CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv 389 2021

CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Number and origin of publicly available SARS-CoV-2 sequence data over time. The 395 histogram shows the number of SARS-CoV-2 assembly sequences deposited at GISAID and NCBI 396 Virus and NGS data deposited at SRA as of 02OCT2020

Countries summarized as "other" include: Algeria

Overview of the 2,592 distinct non-synonymous mutations in the spike protein of SARS-412

CoV-2 detected in genome assemblies and NGS data sets

Author U.S. is co-founder, shareholder and CEO at BioNTech SE. The remaining authors declare that 265 the research was conducted in the absence of any commercial or financial relationships that could be 266 construed as a potential conflict of interest. 267

We thank Pablo Riesgo Ferreiro and Patrick Sorn for critical discussions. We gratefully acknowledge 269 the authors from the originating laboratories responsible for obtaining the specimens, as well as the